HBIO Fail-to-Deliver
Harvard Bioscience, Inc. (HBIO) operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry, with a market capitalization near $37.1M, listed on NASDAQ, employing roughly 328 people, carrying a beta of 1.51 to the broader market. Harvard Bioscience, Inc. Led by John D. Duke, public since 2000-12-07.
No records carrying symbol HBIO appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 7, 2026 through September 30, 2026.
Most recent fail-to-deliver in our records: August 6, 2026.
Frequently asked HBIO fail-to-deliver questions
- Has HBIO had any fails-to-deliver recently?
- No records carrying symbol HBIO appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 7, 2026 through September 30, 2026. Most recent fail-to-deliver in our records: August 6, 2026. The SEC publishes the first half of each month at the month's end and the second half around the 15th of the next month, so this check covers settlement dates through September 30, 2026.
- What does it mean when HBIO is absent from the SEC fails-to-deliver data?
- The SEC's files give the aggregate net balance of shares that failed to be delivered in NSCC's Continuous Net Settlement system, by security and settlement date. Since September 16, 2008 a security has a record for every settlement date on which that balance was above zero, and none when it was zero. This check is by symbol, so a fail reported only under a CUSIP or a former symbol is not counted.
Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.
Learn how fails-to-deliver is reported and how to read the data →